CD200R1 Antibody [Unconjugated]

Human immature dentritic cells differentated from human peripheral blood mononuclear cell derived CD14+ cells treated with 20 ng/mL Recombinant Human IL‑4 (Catalog # 204-IL) and 50 ng/mL Recombinant Human GM‑CSF (Catalog # 215-GM) for 6‑7 days were stained with Goat Anti-Human CD200 R1 Antigen Affinity‑purified Polyclonal Antibody(Catalog # AF3414, filled histogram) or isotype control (Catalog # AB-108-C, open histogram), followed by Donkey Anti-Goat IgG (H+L) Phycoerythrin (Catalog # F0107).

• Reactivity: Hu
• Applications: WB, Flow, B/N, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CD200R1 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human CD200 R1
  Ala27-Leu266
  Accession # AAQ19772
• Specificity: Detects human CD200 R1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross-reactivity with recombinant mouse CD200 R1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CD200R1
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD200R1 Antibody [Unconjugated]

• CD200 R1
• CD200 receptor 1
• CD200R1
• CD200RMOX2Rcell surface glycoprotein CD200 receptor 1
• Cell surface glycoprotein OX2 receptor 1
• cell surface glycoprotein receptor CD200
• CRTR2
• HCRTR2
• MOX2 receptor
• MOX2R
• OX2RCD200 cell surface glycoprotein receptor

Background

CD200 R1, also known as OX-2 receptor, is a 90 kDa transmembrane protein in the immunoglobulin superfamily (1‑3). The standard human CD200 R1 cDNA encodes a 325 amino acid (aa) precursor that includes a 28 aa signal sequence, a 215 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 61 aa cytoplasmic domain. The ECD is composed of one Ig‑like V‑type domain and one Ig‑like C2‑type domain (4). Within the ECD, human CD200 R1 shares 56% aa sequence identity with mouse and rat CD200 R1. Alternate splicing of the human CD200 R1 mRNA generates four isoforms, two of which are truncated in the Ig-C2 domain and are likely secreted. The protein expressed here contains a mature region that is identical to that of the standard form. There is an N‑terminal extension of 25 aa that, in the standard form, is part of the signal sequence. In human, a separate CD200 R12 gene encodes a protein that shares 81% ECD aa identity with CD200 R11. In mouse, at least four genes for CD200 R1-like molecules have been described (4 - 6). CD200 R1 expression is restricted primarily to mast cells, basophils, macrophages, and dendritic cells (7‑9), while its ligand, CD200, is widely distributed (10). Disruption of this receptor-ligand system by knockout of the CD200 gene in mice leads to increased macrophage number and activation and predisposition to autoimmune disorders (11). Association of CD200 with CD200 R1 takes place between their respective N‑terminal Ig‑like domains (12). The capacity of CD200 R1-like molecules to interact with CD200 is controversial (5, 13). CD200 R1 propagates inhibitory signals despite its lacking a cytoplasmic ITIM (immunoreceptor tyrosine-based inhibitory motif) (8, 9, 14, 15) CD200 R1-like molecules, in contrast, are potentially activating receptors by means of their association with DAP12 (4, 6).

1. Rosenblum, M.D. et al. (2006) J. Dermatol. Sci. 41:165.
2. Gorczynski, R.M. (2005) Curr. Opin. Invest. Drugs 6:483.
3. Barclay, A.N. et al. (2002) Trends Immunol. 23:285.
4. Wright, G.J. et al. (2003) J. Immunol. 171:3034.
5. Hatherley, D. et al. (2005) J. Immunol. 175:2469.
6. Voehringer, D. et al. (2004) J. Biol. Chem. 279:54117.
7. Shiratori, I. et al. (2005) J. Immunol. 175:4441.
8. Cherwinski, H.M. et al. (2005) J. Immunol. 174:1348.
9. Fallarino, F. et al. (2004) J. Immunol. 173:3748.
10. Wright, G.J. et al. (2001) Immunology 102:173.
11. Hoek, R.M. et al. (2000) Science 290:1768.
12. Hatherley, D. and A.N. Barclay (2004) Eur. J. Immunol. 34:1688.
13. Gorczynski, R. et al. (2004) J. Immunol. 172:7744.
14. Jenmalm, M.C. et al. (2006) J. Immunol. 176:191.
15. Zhang, S. et al. (2004) J. Immunol. 173:6786.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CD200R1 Antibody (AF3414)(2)

Publications using AF3414

• V Singh, S Kushwaha, JA Ansari, S Gangopadhy, SK Mishra, RK Dey, AK Giri, S Patnaik, D Ghosh MicroRNA-129-5p-regulated microglial expression of the surface receptor CD200R1 controls neuroinflammation The Journal of Biological Chemistry, 2021-12-22;0(0):101521. 2021-12-22 [PMID: 34952004] (Western Blot, Human)
• Ramsay , Alan G, Clear , Andrew J, Fatah , Rewas, Gribben , John G Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood, 2012-04-30;120(7):1412-21. 2012-04-30 [PMID: 22547582] (Neutralization, Human)

Bioinformatics

• Gene Symbol: CD200R1
• Uniprot:
  • AAQ19772()